CoChat
Sign Up
Cited by 174

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis

Kim, Rebecca G., Loomba, Rohit, Prokop, Larry J., Singh, Siddharth·2017·Clinical Gastroenterology and Hepatology
DOI 10.1016/j.cgh.2017.04.039PMC PMC5605397
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2017.04.039

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 53

  1. Xu, 2016, Deaths: final data for 2013, National Vital Statistics Reports, 64, 1
  2. Grundy, 1988, HMG-CoA reductase inhibitors for treatment of hypercholesterolemia, N Engl J Med, 319, 24, 10.1056/NEJM198807073190105 · DOI
  3. Endo, 1976, Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity, FEBS Lett, 72, 323, 10.1016/0014-5793(76)80996-9 · DOI
  4. Tsujita, 1979, Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, Atherosclerosis, 32, 307, 10.1016/0021-9150(79)90174-6 · DOI
  5. Shigematsu, 1979, Treatment of hypercholesterolemia with a HMG CoA reductase inhibitor (CS-500). I. Phase I study in normal subjects, Geriatr Med, 17, 1564
  6. Yamamoto, 1980, Therapeutic effects of ML-236B in primary hypercholesterolemia, Atherosclerosis, 35, 259, 10.1016/0021-9150(80)90124-0 · DOI
  7. Tobert, 1982, Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, in healthy volunteers, J Clin Invest, 69, 913, 10.1172/JCI110530 · DOI
  8. 1986, Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia: a multicenter study, JAMA, 256, 2829, 10.1001/jama.1986.03380200067023 · DOI
  9. Havel, 1987, Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multicenter study, Ann Intern Med, 107, 609, 10.7326/0003-4819-107-5-609 · DOI
  10. Musial, 2001, Anti-inflammatory effects of simvastatin in subjects with hypercholesterolemia, Int J Cardiol, 77, 247, 10.1016/S0167-5273(00)00439-3 · DOI
  11. Ridker, 2001, Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia, Circulation, 103, 1191, 10.1161/01.CIR.103.9.1191 · DOI
  12. Albert, 2001, The pravastatin inflammation CRP evaluation (PRINCE): rationale and design, Am Heart J, 141, 893, 10.1067/mhj.2001.115297 · DOI
  13. Lefer, 2002, Statins as potent antiinflammatory drugs, Circulation, 106, 2041, 10.1161/01.CIR.0000033635.42612.88 · DOI
  14. McGirt, 2002, Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage, Stroke, 33, 2950, 10.1161/01.STR.0000038986.68044.39 · DOI
  15. Kalinowski, 2002, Increased nitric oxide bioavailability in endothelial cells contributes to the pleiotropic effect of cerivastatin, Circulation, 105, 933, 10.1161/hc0802.104283 · DOI
  16. Laufs, 1998, Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors, Circulation, 97, 1129, 10.1161/01.CIR.97.12.1129 · DOI
  17. Laufs, 1997, Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase, J Biol Chem, 272, 31725, 10.1074/jbc.272.50.31725 · DOI
  18. Hernandez-Perera, 1998, Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells, J Clin Invest, 101, 2711, 10.1172/JCI1500 · DOI
  19. Llevadot, 2001, HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells, J Clin Invest, 108, 399, 10.1172/JCI200113131 · DOI
  20. Anderson, 1995, The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion, N Engl J Med, 332, 488, 10.1056/NEJM199502233320802 · DOI
  21. Treasure, 1995, Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease, N Engl J Med, 332, 481, 10.1056/NEJM199502233320801 · DOI
  22. O'Driscoll, 1997, Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month, Circulation, 95, 1126, 10.1161/01.CIR.95.5.1126 · DOI
  23. Zafra, 2004, Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis, Gastroenterology, 126, 749, 10.1053/j.gastro.2003.12.007 · DOI
  24. Abraldes, 2007, Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats, J Hepatol, 46, 1040, 10.1016/j.jhep.2007.01.020 · DOI
  25. Moreno, 2009, Atorvastatin attenuates angiotensin II-induced inflammatory actions in the liver, Am J Physiol Gastrointest Liver Physiol, 296, G147, 10.1152/ajpgi.00462.2007 · DOI
  26. Trebicka, 2010, Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells, J Hepatol, 53, 702, 10.1016/j.jhep.2010.04.025 · DOI
  27. Mura, 2013, Effects of simvastatin administration on rodents with lipopolysaccharide-induced liver microvascular dysfunction, Hepatology, 57, 1172, 10.1002/hep.26127 · DOI
  28. Marrone, 2015, KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins, Gut, 64, 1434, 10.1136/gutjnl-2014-308338 · DOI · Paper page
  29. Singh, 2013, Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis, Gastroenterology, 144, 323, 10.1053/j.gastro.2012.10.005 · DOI
  30. Tsan, 2012, Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection, Value Health, 15, A602, 10.1016/j.jval.2012.08.008 · DOI
  31. El-Serag, 2009, Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes, Gastroenterology, 136, 1601, 10.1053/j.gastro.2009.01.053 · DOI · Paper page
  32. Abraldes, 2009, Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial, Gastroenterology, 136, 1651, 10.1053/j.gastro.2009.01.043 · DOI
  33. Abraldes, 2016, Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis, Gastroenterology, 150, 1160, 10.1053/j.gastro.2016.01.004 · DOI · Paper page
  34. Huang, 2016, Statins reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study, Am J Gastroenterol, 111, 976, 10.1038/ajg.2016.179 · DOI
  35. Kumar, 2014, Statin use in patients with cirrhosis: a retrospective cohort study, Dig Dis Sci, 59, 1958, 10.1007/s10620-014-3179-2 · DOI
  36. Mohanty, 2016, Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis, Gastroenterology, 150, 430, 10.1053/j.gastro.2015.10.007 · DOI
  37. Pollo-Flores, 2015, Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial, Dig Liver Dis, 47, 957, 10.1016/j.dld.2015.07.156 · DOI
  38. Simon, 2016, Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES, Hepatology, 64, 47, 10.1002/hep.28506 · DOI
  39. Simon, 2015, Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C, J Hepatol, 62, 18, 10.1016/j.jhep.2014.08.013 · DOI
  40. Yang, 2015, Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection, J Hepatol, 63, 1111, 10.1016/j.jhep.2015.07.006 · DOI
  41. Hsiang, 2015, Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: a propensity score landmark analysis, J Hepatol, 63, 1190, 10.1016/j.jhep.2015.07.009 · DOI
  42. Oliver, 2016, Statin drugs decrease progression to cirrhosis in HIV/hepatitis C virus coinfected individuals, AIDS, 30, 2469, 10.1097/QAD.0000000000001219 · DOI
  43. Liberati, 2009, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, PLoS Med, 6, e1000100, 10.1371/journal.pmed.1000100 · DOI · Paper page
  44. DerSimonian, 1986, Meta-analysis in clinical trials, Control Clin Trials, 7, 177, 10.1016/0197-2456(86)90046-2 · DOI · Paper page
  45. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  46. Guyatt, 2013, Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes, J Clin Epidemiol, 66, 151, 10.1016/j.jclinepi.2012.01.006 · DOI · Paper page
  47. Chang, 2017, Statins decrease the risk of decompensation in HBV- and HCV-related cirrhosis: a population-based study, Hepatology
  48. Bang, 2016, The impact of statins on mortality in patients with compensated or decompensated alcoholic cirrhosis in a nationwide retrospective study, Hepatology, 54, 131A
  49. Butt, 2015, Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES, Hepatology, 62, 365, 10.1002/hep.27835 · DOI
  50. Gupta, 1998, Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats, Hepatology, 28, 926, 10.1002/hep.510280405 · DOI
  51. Rockey, 1998, Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension, Gastroenterology, 114, 344, 10.1016/S0016-5085(98)70487-1 · DOI
  52. Shah, 1999, Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat, Gastroenterology, 117, 1222, 10.1016/S0016-5085(99)70408-7 · DOI
  53. Targownik, 2015, Understanding and avoiding immortal-time bias in gastrointestinal observational research, Am J Gastroenterol, 110, 1647, 10.1038/ajg.2015.210 · DOI

Cited by

Sorted by citations

See all 174

Metadata

Authors
Kim, R. G., Loomba, R., Prokop, L. J., & Singh, S.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2017-10
Volume
15
Issue
10
Pages
1521-1530.e8
ISSN
1542-3565
DOI
10.1016/j.cgh.2017.04.039
PMC
PMC5605397
Cited by
174
References
2
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review